6541 — Tanvex Biopharma Share Price
- TWD6.46bn
- TWD7.81bn
- TWD61.41m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 7.87 | ||
Price to Tang. Book | 7.9 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 105.25 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -87.9% | ||
Return on Equity | -193.18% | ||
Operating Margin | -3434.93% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | TWDm | n/a | 0.3 | 5.41 | 22.4 | 61.41 | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Company’s product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
Directors
- Yun Yen CHM
- Helena Makagiansar DGM
- Mike Parker DGM
- Yongjian Wu DGM
- Kaiwen Yang DGM
- Allen Chao DRC
- David Hsia DRC
- Tamon Tseng DRC
- Yuxing Xue DRC
- Jin-Pau Tsai IND
- Taichang Wang IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 8th, 2013
- Public Since
- August 13th, 2015
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 133,962,867
- Address
- Floor 4, Willow House, Cricket Square,, GRAND CAYMAN, KY1-1112
- Web
- http://www.tanvex.com/
- Phone
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for 6541
Q1 2024 Tanvex BioPharma Inc Earnings Release
May 2024 Tanvex BioPharma Inc Corporate Sales Release
Tanvex BioPharma Inc Annual Shareholders Meeting
June 2024 Tanvex BioPharma Inc Corporate Sales Release
Q2 2024 Tanvex BioPharma Inc Earnings Release
July 2024 Tanvex BioPharma Inc Corporate Sales Release
August 2024 Tanvex BioPharma Inc Corporate Sales Release
September 2024 Tanvex BioPharma Inc Corporate Sales Release
Similar to 6541
Abnova Taiwan
Taiwan Stock Exchange
Applied BioCode
Taiwan Stock Exchange
Energenesis Biomedical Co
Taiwan Stock Exchange
Kim Forest Enterprise Co
Taiwan Stock Exchange
PHARMAESSENTIA
Taiwan Stock Exchange
FAQ
As of Today at 19:21 UTC, shares in Tanvex Biopharma are trading at TWD48.25. This share price information is delayed by 15 minutes.
Shares in Tanvex Biopharma last closed at TWD48.25 and the price had moved by -37.9% over the past 365 days. In terms of relative price strength the Tanvex Biopharma share price has underperformed the FTSE Developed Asia Pacific Index by -37.47% over the past year.
The overall consensus recommendation for Tanvex Biopharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Tanvex Biopharma does not currently pay a dividend.
Tanvex Biopharma does not currently pay a dividend.
Tanvex Biopharma does not currently pay a dividend.
To buy shares in Tanvex Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD48.25, shares in Tanvex Biopharma had a market capitalisation of TWD6.46bn.
Here are the trading details for Tanvex Biopharma:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 6541
Based on an overall assessment of its quality, value and momentum Tanvex Biopharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tanvex Biopharma. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -29.41%.
As of the last closing price of TWD48.25, shares in Tanvex Biopharma were trading -24.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Tanvex Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD48.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Tanvex Biopharma's management team is headed by:
- Yun Yen - CHM
- Helena Makagiansar - DGM
- Mike Parker - DGM
- Yongjian Wu - DGM
- Kaiwen Yang - DGM
- Allen Chao - DRC
- David Hsia - DRC
- Tamon Tseng - DRC
- Yuxing Xue - DRC
- Jin-Pau Tsai - IND
- Taichang Wang - IND